Skyhawk Therapeutics today presented nine-month interim results from its ongoing Phase 1 clinical trial of SKY-0515 in patients with Huntington's Disease. The data continues to demonstrate meaningful and sustained reductions in mutant huntingtin protein.
CLINICAL UPDATE
Nine Month Interim Results from Phase 1 Clinical Trial of SKY-0515
Updated Phase 1 data shows sustained HTT lowering and clinical benefit through nine months of treatment with SKY-0515 in Huntington's Disease patients.